Key Developments: Natus Medical Inc (BABY.OQ)
13.64USD
1 Aug 2013
$0.85 (+6.65%)
$12.79
$12.95
$13.81
$12.52
103,032
56,306
$15.18
$9.65
Latest Key Developments (Source: Significant Developments)
Natus Medical Inc Issues Q3 2013 Outlook; Revenue Outlook Below Analysts' Estimates; Issues Q4 2013 Outlook Below Analysts' Estimates; Lowers FY 2013 Outlook; Issues Q3 2013 Charge Outlook
Natus Medical Inc announced that for the third quarter 2013, it expects to report revenue of $80 million to $82 million and non-GAAP earnings per share of $0.18 to $0.21. For the fourth quarter 2013, the Company expects to report revenue of $84 million to $88 million and non-GAAP earnings per share of $0.22 to $0.25. For fiscal 2013 the Company expects to report revenue of $332 million to $338 million and non-GAAP earnings per share (EPS) of $0.76 to $0.82. The Company expects to record a restructuring charge of approximately $2 million during the third quarter 2013 associated with a plan to restructure and streamline operations and reduce costs. Non-GAAP earnings per share estimates do not include these estimated restructuring charges. The Company's fiscal 2013 and quarterly non-GAAP earnings per share guidance exclude amortization of acquisition related intangibles, acquisition related charges, restructuring charges, and their related tax effects. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $85 million and EPS of $0.18 for the third quarter of 2013; revenue of $95 million and EPS of $0.30 for the fourth quarter of 2013; and revenue of $352 million and EPS of $0.76 for fiscal 2013. Full Article
Natus Medical Inc Lowers Q2 2013 Revenue Guidance
Natus Medical Inc announced that for second quarter of 2013, it expects revenue to be between $81 million and $82 million versus previous guidance of $86 million to $90 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $88 million for second quarter of 2013. Full Article
Natus Medical Inc Reaffirms Q2 2013 Guidance; Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Natus Medical Inc reaffirmed second quarter 2013 guidance and expects revenue in the range of $86 million to $90 million and non-GAAP earnings per share (EPS) in the range of $0.17-$0.20. For fiscal 2013 the Company expects to report revenue of $362 million to $367 million and non-GAAP earnings per share of $0.85 to $0.88. The Company most recently reported that it expected to report non-GAAP earnings per share of $0.84 to $0.87. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $89 million and EPS of $0.19 for second quarter of 2013; revenue of $364 million and EPS of $0.84 for fiscal 2013. Full Article
Natus Medical Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates
Natus Medical Inc announced that for fiscal 2013, it expects revenue of $362 million to $367 million and non-GAAP earnings per share of $0.84 to $0.87. For second quarter of 2013, it expects revenue between $86 million to $90 million and non-GAAP earnings per share of $0.17 to $0.20. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $364 million and EPS of $0.84 for fiscal 2013; revenue of $90 million and EPS of $0.19 for second quarter of 2013. Full Article
Natus Medical Inc Appoints Jonathan Kennedy As Chief Financial Officer
Natus Medical Inc announced that it has named Jonathan Kennedy to the position of Senior Vice President and Chief Financial Officer. Full Article
Natus Medical Inc Reaffirms FY, Q1 2013 Guidance
Natus Medical Inc reiterated financial guidance for fiscal 2013 and expects to report revenue in the range of $362-$367 million and non-GAAP earnings per share of $0.81 to $0.84. For the first quarter of 2013, the Company expects to report revenue in the range of $83-$85 million and non-GAAP earnings per share of $0.09 to $0.10. The revenue and non-GAAP earnings per share guidance include the impact of the acquisition of the Grass Technologies Product Group. The guidance does not give effect to the impact of any other potential future acquisitions. The Company's non-GAAP earnings per share guidance excludes charges for amortization expense associated with intangible assets from prior acquisitions and the Grass Technologies acquisition, which the Company expects to be approximately $6.4 million and $1.6 million for the full year and first quarter 2013, respectively, and which the Company expects will reduce GAAP earnings per share by approximately $0.14 and $0.03 for the respective periods. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $362 million and EPS of $0.83 for fiscal 2013; and revenue of $84 million and EPS of $0.09 for the first quarter of 2013. Full Article
Natus Medical Inc Issues FY 2013 Guidance Above Analysts' Estimates; Issues Q1 2013 Mixed Guidance
Natus Medical Inc announced that for fiscal 2013, it expects to report revenue of $362 million to $367 million and non-GAAP earnings per share (EPS) of $0.81 to $0.84. For the first quarter of 2013, the Company expects to report revenue of $83 million to $85 million and non-GAAP earnings per share (EPS) of $0.09 to $0.10. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $347 million and EPS of $0.76 for fiscal 2013; and revenue of $82 million and EPS of $0.13 for the first quarter of 2013. Full Article
Natus Medical Inc to Acquire Grass Technologies Product Group from Astro-Med Inc
Natus Medical Inc and Astro-Med Inc announced that the companies have entered into a definitive agreement for Natus to acquire the Grass Technologies Product Group from Astro-Med. The Grass Technologies Product Group includes clinically differentiated neurodiagnostic and monitoring products, including a portfolio of polysomnography (PSG) and electroencephalography (EEG) systems for both clinical and research use and related accessories and electrodes. The transaction is expected to close on January 31, 2013. Natus will fund the approximate $18.6 million cash purchase price with existing cash and borrowings under its credit facility. Astro-Med will retain its Grass manufacturing facility and the companies have entered into an agreement whereby Astro-Med will continue to manufacture the Grass products and provide other transition services for a period of time, after which Natus will acquire any remaining inventory. Full Article
Natus Medical Inc Lowers FY 2012 Revenue Guidance; Lowers High End Of Prior FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates; Issues Q4 2012 Guidance In Line With Analysts' Estimates
Natus Medical Inc updated its fiscal 2012 financial guidance. For fiscal 2012, the Company expects to report revenue of $293 million to $296 million and non-GAAP earnings per share of $0.58 to $0.61. The Company had earlier said that it expected to report revenue of $295 million to $300 million and non-GAAP earnings per share of $0.58 to $0.63. For the fourth quarter of 2012, the Company expects to report revenue of $92 million to $95 million and non-GAAP earnings per share (EPS) of $0.25 to $0.28. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $295 million and EPS of $.60 for fiscal 2012; and revenue of $95 million and EPS of $.28 for the fourth quarter of 2012. Full Article
Natus Medical Inc Reaffirms Q3, FY 2012 Guidance-Conference Call
Natus Medical Inc announced that for fiscal 2012, it expects revenue in the range of $295 million to $300 million with earnings of $0.58 to $0.63. For the third quarter of 2012, it expects revenue in the range of $80 million to $82 million and EPS in the range of $0.12 to $0.14. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $295 million and EPS of $0.60 for fiscal 2012; revenue of $81 million and EPS of $0.13 for the third quarter of 2012. Full Article

Earnings vs.
Estimates